Stocktoria
AbCellera Biologics Inc. ABCL
AbCellera Biologics Inc. (ABCL) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $75.1M at a -194.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.489 |
| Retained earnings / assets | -0.022 |
| EBIT / assets | -0.16 |
| Equity / liabilities | 2.479 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | 4/9 | 4.67 | — | +160.6% |
| CTMX | CytomX Therapeutics, Inc. | 1/9 | -10.12 | — | -44.8% |
| BCYC | BICYCLE THERAPEUTICS PLC | 1/9 | 5.27 | — | +105.8% |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | 3/9 | -1.34 | — | +153.5% |
| VRDN | Viridian Therapeutics, Inc.DE | 2/9 | 2.72 | — | — |
| ETON | Eton Pharmaceuticals, Inc. | 5/9 | -2.05 | — | +104.9% |
| RMTI | ROCKWELL MEDICAL, INC. | 2/9 | -18.33 | — | -31.8% |
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
FAQ
Is ABCL financially healthy?
AbCellera Biologics Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ABCL pay a dividend?
No, AbCellera Biologics Inc. does not currently pay a dividend.
How profitable is ABCL?
In FY2025, AbCellera Biologics Inc. had a net margin of -194.9% and a return on equity of -15.1%.
What is the analyst price target for ABCL?
The average Wall-Street price target for AbCellera Biologics Inc. is $10.43, about 0.7% above the recent price, from 7 analysts (consensus: strong buy).
Is ABCL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AbCellera Biologics Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.